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Abstract
Rotaviruses are major causes of infectious gastroenteritis in
humans and other animals. We found that a variety of protease
inhibitors suppressed the replication of the SA-1 1 strain of
rotavirus in MA-104 cell cultures. Three of these compounds,
leupeptin, pentamidine, and bis (5-amidino-2-benzimidazolyl)
methane (BABIM) also restricted the intestinal replication of
the murine strain of rotavirus when protease inhibitor and
virus were administered simultaneously to suckling mice. Re-
peated administration of BABIM resulted in significantly re-
duced levels of intestinal rotaviral antigen even if administra-
tion of the compound was begun as late as 48 h after viral
inoculation. Additionally, BABIM-treated animals had signifi-
cantly less intestinal replication of rotavirus than did placebo-
treated controls when placed in a heavily rotavirus-contami-
nated environment. The use of protease inhibitors represents a
novel approach to the control of this important gastrointestinal
pathogen and is a potential modality for the prevention and
treatment of diseases caused by other enteric viruses, for which
proteolytic cleavage is necessary for efficient replication.
Introduction
Rotaviruses are double-stranded RNA viruses of the family
Reoviridae that have been implicated as important causative
agents of acute gastroenteritis in humans and other animals
(1-3). Numerous epidemiological studies have indicated that
rotaviruses are a major cause of morbidity in children living in
developed countries and of serious and potentially fatal gas-
troenteritis in children living in the developing areas of the
world (4-6). Additionally, these viruses have been implicated
as causative agents of gastroenteritis occurring in nursing
homes (7, 8), travelers (9, 10), adult contacts of ill children (1 1,
12), and have been identified as etiologic agents of severe gas-
troenteritis in patients rendered immunodeficient because of
cancer chemotherapy or other immunodeficiency conditions
(13, 14). Because of the importance of rotavirus infections,
intensive efforts have been directed at developing attenuated
strains of rotavirus that might be capable of providing long-
term immunity after oral administration (15, 16). However, it
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can be anticipated that there will be large groups of humans
and animals that will not respond efficiently to oral immuniza-
tion with attenuated rotaviruses due to immunologic imma-
turity or deficiency (13, 14, 17, 18), consumption of milk con-
taining rotaviral antibodies (19, 20), nutritional deficiencies
(21), or interference with rotaviral replication due to the rep-
lication of other intestinal viruses (22). Furthermore, the anti-
genic determinants of a protective immune response have not
been completely delineated. Additionally, active immuniza-
tion would probably not be capable of altering the course of
serious cases of rotavirus gastroenteritis once the infection is
established. Thus, development of antiviral agents that inhibit
the intestinal replication of a wide range of rotaviruses inde-
pendent of the development of an immune response would be
a useful alternative strategy for the prevention and treatment
of rotaviral infections in high-risk populations.
It has been known for several years that trypsin and other
intestinal proteases enhance the replication of rotaviruses in
vitro (23, 24) and probably also in vivo (25). This activation is
the result of the cleavage of viral polypeptides located on the
outer shell of the virus with a subsequent increase in the effi-
ciency of cellular attachment or viral uncoating (26, 27). It is
believed that the same process occurs in the small intestine,
where a high level of protease activity exists and which is the
principal site of rotaviral replication. Recently, a number of
low-molecular weight aromatic diamidines that are potent in-
hibitors of trypsin-like proteases have been synthesized (28,
29). One of these compounds, bis (5-amidino-2-benzimidazo-
lyl) methane (BABIM),' is the most potent synthetic, revers-
ible inhibitor of trypsin yet identified. This compound has
been reported to possess a significant suppressive effect on the
in vitro cytopathology and in vitro and in vivo yield of respira-
tory syncytial virus, a respiratory virus that requires proteolysis
for efficient replication (30-32). We thus investigated the ef-
fect of BABIM, and a variety of drugs that inhibit protease
function on the in vitro replication of rotavirus as well as on
the replication of rotavirus in the intestinal tract ofexperimen-
tal animals.
Methods
Viruses. The SA-l 1 strain that we used was originally obtained from
Dr. H. Malherbe, University of Texas, San Antonio, Texas. The virus
was plaque purified and serially passaged in MA- 104 cells using MEM
containing 0.5 ,g/ml of porcine trypsin (Sigma Chemical Co., St.
Louis, MO) by means ofpreviously described methods (33). The strain
that we used can be propagated in MA- 104 cells in roller tubes without
additional trypsin but requires the presence of trypsin for the genera-
tion of visible plaques.
1. Abbreviations used in this paper: BABIM, bis (5-amidino-2-benzi-
midazolyl); EDIM, epizootic diarrhea of infant mice; MIDOO, 100%
mouse infective dose.
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For some experiments, an aliquot of SA-11 was passaged three
times in MA-104 cells in MEM without trypsin to generate a popula-
tion of virus that was not trypsin activated. At the same time, an
equivalent aliquot was passaged under identical conditions in the pres-
ence of trypsin. These strains were designated SA'- and SAt+, respec-
tively. The virus was passaged at a dilution of 1:10 at each step. The
final concentration of trypsin in the SA'- aliquots was thus < 0.001
Afg/ml.
Murine rotavirus or epizootic diarrhea ofinfant mice (EDIM) virus
used for the animal experiments was originally obtained from Dr.
Michael Collins, Microbiological Associates, Bethesda, MD. Virus for
mouse inoculation was isolated from EDIM virus containing intestinal
homogenates and purified on CsCl gradients using procedures pre-
viously described (34). The infectivity of the purified virus was deter-
mined by orally inoculating litters of5-6-d-old mice with 10 ttl ofserial
10-fold dilutions ofthe viral preparation. 3 d later, mice were evaluated
for diarrhea by examining the distal colon for the presence of bright
yellow, liquid contents that are characteristic of EDIM virus-induced
diarrhea. The highest dilution of the viral preparation that resulted in
diarrhea in all of the animals in the litter was defined as the 100%
mouse infectious dose (MID100).
Animals. Pregnant CD- I mice were purchased from a commercial
supplier (Charles River Breeding Laboratories, Inc., Portage, MI). All
animals were bled at the time of arrival to assure that they were free of
rotaviral antibodies. The mice were then placed in individual cages in
positive pressure ventilation isolators, given food and water ad lib., and
allowed to give birth naturally. At the beginning of each experiment,
sera, and intestines were collected from two suckling mice in each litter
to assure that the animals had remained free of serum rotaviral anti-
bodies and intestinal rotaviral antigen. Suckling mice from all litters
were combined and randomly divided equally among the dams in
preparation for experimental inoculation. Suckling mice remained
with the dams throughout the experiments.
Test compounds. The following protease inhibitors were obtained
from Sigma Chemical Co., St. Louis, MO or Peninsula Laboratories,
Santa Clara, CA: soybean trypsin inhibitor, human alpha-l-antitryp-
sin, antipain, bestatin, leupeptin, and chymostatin. Pentamidine and
BABIM were synthesized according to previously described methods
(28, 29).
Plaque assays. The effect of the various protease inhibitors on the
growth of the SA-I 1 strain of rotavirus was determined by plaque
inhibition methods performed by a modification of previously de-
scribed rotavirus plaquing techniques (35). Briefly, SA- 1I virus diluted
to a concentration of - 100 plaque-forming units per milliliter in
MEM without added serum was mixed with an equal volume of pro-
tease inhibitor at varying concentrations and adsorbed on MA- 104 cell
monolayers for 2 h at 370C. This mixture was then decanted and the
cells were covered with agarose containing trypsin at a concentration of
0.5 ,g/ml, as well as the same concentration of protease inhibitor used
in the absorptions. A second overlay containing the vital stain neutral
red was added 3 d later and plaques representing infected cells that did
not take up the vital stain were counted using standard methods. For
each concentration of inhibitor, a percentage inhibition was calculated
by comparisons with the number of plaques generated in wells pro-
cessed in an identical fashion in the absence of protease inhibitor.
Animal inoculation. The effect ofprotease inhibitors on the in vivo
replication of rotaviruses was evaluated in the mouse model of rota-
viral infection. To do this, nine parts of a selected test compound
diluted with PBS containing 0.01% CaC12 and 0.01% MgCl2. 6H20
(Ca, Mg-PBS) to a concentration of 10 mg/ml was mixed with one part
of EDIM virus containing 100 MID100 of EDIM virus. 2 d after viral
inoculation, the distal colon of each mouse was examined for the
presence ofliquid contents and the entire intestinal tract was collected
for quantitation of rotaviral antigen by enzyme immunoassay.
Intestinal specimens. Intestinal tracts collected from suckling mice
were wrapped individually, and immediately frozen at -70°C. In prep-
aration for rotavirus antigen measurement by enzyme immunoassay,
the individual samples were ground in hand-held, Ten Broeck type
tissue grinders (CVWR Scientific, Bridgeport, NJ) and suspended in
sufficient Ca, Mg-PBS to produce a 10% (wt/vol) suspension. After a
second freezing and thawing, the samples were centrifuged at 12,000 g
for 5 min to pellet particulate material. The resulting supernatants
were collected for enzyme immunoassay.
Immunoassays. A solid phase, sandwich-type, enzyme immunoas-
say was used to quantitate rotaviral antigens in murine intestinal ho-
mogenates. Wells of polystyrene microtiter plates (Immulon II; Dyna-
tech Laboratories, Alexandria, VA) were first coated with either non-
immune chicken serum or chicken anti-EDIM virus serum that had
been diluted in carbonate buffer (pH 9.8). After overnight incubation
at 4VC, the wells were washed with PBS containing 0.5% Tween 20
(PBS-Tween), covered with test intestinal homogenate, and again
incubated overnight at 4VC. The wells were then washed with PBS-
Tween and the quantity of rotaviral antigen bound to the antibody-
coated solid phase was determined by the addition of guinea pig anti-
serum to EDIM virus, followed by affinity-purified, peroxidase-
labeled, goat antibody to guinea pig IgG, and substrate consisting of0.4
mg of o-phenylenediamine and 0.4 gl of 30% H202/ml of 0.01 M
citrate buffer (pH 5.0). The action of enzyme on substrate was quanti-
tated in a spectrophotometer (Biotek Instruments Inc., Burlington,
VT) at a wavelength of 450 nm. Pooled intestinal homogenates ob-
tained from EDIM virus-free or EDIM virus-infected suckling mice
served as the negative and positive controls, respectively on each plate.
The net OD for each test sample was determined by subtracting the
OD readings obtained from wells coated with nonimmune chicken
serum from the OD readings obtained from wells coated with EDIM
virus-immune chicken serum. To control for plate-to-plate variations
in OD readings, rotaviral antigen levels in each test sample were ex-
pressed as a percent of the positive control samples on that particular
plate. (It was noted that BABIM at concentrations ofup to 1 mg/ml did
not effect antigen measurement in the enzyme immunoassay.) Values
obtained for test compound-treated and control-treated animals were
compared by Wilcoxon Rank Sum analysis to determine if observed
differences were statistically significant. Values for graphic display
were determined by expressing the rotaviral antigen levels in test
compound-treated animals as a percent of the mean rotavirus antigen
level in the PBS-treated control animals. Generally, the intestinal
contents of infected, untreated animals yielded OD values ranging
from 0.8-1.0 U.
Preinoculation serum samples were analyzed for rotaviral antibod-
ies using both antibody binding (36) and inhibition (37) enzyme im-
munoassays similar to those previously described.
Pharmacokinetics. The test compound, BABIM, was labeled with
tritium-[3H] by tritium exchange methods (New England Nuclear,
Boston, MA). The specific activity of the compound was 8.7 X I05
cpm/gg BABIM. The [3H] BABIM (106 counts) was intragastrically
administered to 8-1 2-d-old suckling mice via a 24-gauge gavage needle
and at selected intervals, plasma, urine, stomach, intestinal wash, and
small intestine were collected from each animal (three to four mice per
time point). Specimens were weighed and digested with 2 ml NCS
tissue solubilizer (Amersham Corp., Arlington Heights, IL) at 37°C for
48 h with occasional shaking. The digest was neutralized with glacial
acetic acid (34 Ml/ml of NCS) and cooled to room temperature. 20 ml
ofOCS liquid scintillant (Amersham Corp.) were added to each sample
and the level of 3H was determined in a liquid scintillation counter.
The distribution ofthe 3H label in each organ was expressed as counts
per minute per 100 milligrams of tissue and was referred to as the raw
counts per minute. To compensate for variation in weight of the mice
at the termination of the experiment, the compensated counts per
minute was determined by the formula: compensated counts per min-
ute = raw counts per minute X (individual body weight at termination
of experiment/mean body weight of all mice at start of experiment).
Results
The effect of protease inhibitors on the in vitro replication of
SA- 11 virus is depicted in Fig. 1. Most of the protease inhibi-

















Figure 1. Effects of various protease inhibitors on the in vitro rep-
lication of SA- 11 rotavirus in MA- 104 cells. The measurements were
performed as described in the text. Each point represents the degree
of inhibition of SA- 1I virus plaque formation induced by treatment
with different concentrations of the protease inhibitors as compared
with controls cultivated in the absence of inhibitor.
tors were capable of suppressing the in vitro replication of
SA- 11 virus at concentrations ranging from 0.5 to 5 jig/ml.
Efficacy was noted with macromolecular compounds such as
alpha- 1 -antitrypsin and soybean trypsin inhibitor and with
low molecular weight compounds such as leupeptin, BABIM,
antipain, and to a lesser extent, pentamidine. Chymostatin, an
inhibitor with specificity for chymotrypsin but no efficacy as a
trypsin inhibitor, did not display any inhibitory activity
against SA- 11 virus.
We performed additional experiments to determine the
relationship between proteolytic activation of virus and the
efficacy of the protease antagonists for the inhibition of viral
plaque formation. For these experiments we passaged a strain
of plaque-purified SA- 11 in MA- 104 cells without trypsin, des-
ignated strain SAt, and we passaged the same strain of SA- 11
in MA- 104 cells in the presence of trypsin at a concentration of
1 ;ig/ml (SAt'). After three passages, the effects of BABIM on
the generation of plaques were assayed in a manner similar to
the other experiments. As depicted in Fig. 2, BABIM inhibited
both the SA'+ and the SAt- strains at concentrations of 5 and 1
jig/ml. However, the inhibition achieved in the case of the
SAt- strain was slightly greater than the inhibition noted with
the SAt+ strain (93 as opposed to 70% inhibition at a BABIM
concentration of 5 mg/ml). The ability ofBABIM to inhibit the
replication of the SAt- strain was decreased to the level noted
for the SAt+ strain by the pretreatment of the virus with trypsin
immediately before infection of the cells. This effect was re-
versed by the simultaneous addition ofBABIM along with the
trypsin in the preincubation (Fig. 2).
The effect of protease inhibitors on the in vivo replication
of rotavirus is depicted in Fig. 3. Mice receiving EDIM virus
that had been pretreated with leupeptin, pentamidine,
BABIM, antipain, or alpha- 1-antitrypsin had significantly less
diarrhea than the Ca, Mg-PBS-treated control animals. Addi-
tionally, markedly lower levels of intestinal rotaviral antigens
were present in animals administered virus pretreated with
leupeptin, pentamidine, or BABIM when compared with the
I.\ "e SA (t+)
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Figure 2. Effect of BABIM on the replication of SA- 11 cultivated in
the presence and absence of trypsin. An aliquot of plaque-purified
SA- 11 was passed three times in MA- 104 cells in roller tubes in the
absence of trypsin, and an aliquot from the same source was passed
three times in the presence of trypsin under cultivation conditions
that were otherwise identical. These strains, designated SA (t-) and
SA (t+) respectively, were used to infect MA- 104 cells in 12-well tis-
sue-culture plates in the presence and absence of BABIM and the
amount of inhibition of plaque formation was quantitated as de-
scribed in the text. In addition, an aliquot of the SA (t-) strain was
activated with trypsin for 120 min at 370C immediately before in-
fection (SA (t-) + Try) and another aliquot was incubated simulta-
neously without trypsin and BABIM for 120 min at 370C immedi-
ately before infection (SA (t-) + Try + BABIM). These treated
strains were added to the MA- 104 cells and the number of plaques
generated was quantitated in a manner identical to that of the other
strains.
control animals. Animals given antipain-treated virus had in-
termediate levels of intestinal rotaviral antigen. Although sig-
nificantly less diarrhea was present in mice receiving alpha-l-
antitrypsin-treated EDIM virus, the levels of intestinal rota-
viral antigen did not significantly differ from control animals.
The compound BABIM was selected for further studies since,
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Figure 3. Effects of various protease inhibitors on the in vivo replica-
tion of EDIM virus. Protease inhibitor at a concentration of 10
Ag/ml was mixed with EDIM virus, incubated at 370C for 30 min
and then fed to suckling mice. Each bar represents the mean rota-
viral antigen level (±SEM) in intestinal homogenates obtained from
test compound treated mice 2 d after EDIM virus inoculation. Data
are expressed as a percentage of the mean rotaviral antigen level in
PBS-treated control animals. Numbers above each bar represent
number of diarrheic mice/total mice examined, *, significantly dif-
ferent (P < 0.05) from controls by Wilcoxon Rank Sum Test. **, sig-
nificantly different (P < 0.05) from controls by Fisher's Exact Test.
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and has been shown to have inhibitory activity for other patho-
genic viruses (30-32).
Additional studies in animals were directed at determining
the kinetics ofBABIM protection. Thus, a single dose of 10 y1
of BABIM (10 mg/ml) was administered orally to 3-7-d-old
suckling mice either one-half, 1, or 2 h before or one-half, 1, or
2 hours after 1 MID100 ofEDIM virus was administered. Only
when BABIM was given one-half hour before virus was the
rotaviral replication inhibited (data not shown).
Because it appeared that J3ABIM had to be administered at
the time of viral infection or shortly before viral infection to
maximally inhibit replication, we decided to determine if re-
peated administration of BABIM following viral inoculation
would inhibit subsequent rotaviral replication. To make this
determination, 7-10-d-old suckling mice were inoculated with
1 MID100 ofmurine rotavirus. Beginning either one-half, 2, 24,
or 48 h after viral inoculation, 10 ,ul ofBABIM (10 mg/ml) was
administered at 9 and I1 a.m. and at 1, 3, and 5 p.m. every day
for the course of the study. Control mice were administered
Ca, Mg PBS at the same times. Rotaviral antigen levels in
intestinal homogenates were determined by enzyme immuno-
assay 2 and 4 d after viral inoculation. Significantly lower
levels of rotaviral antigen were found 2 d after viral inocula-
tion in mice treated with BABIM beginning one-half, 2, or 24
h after EDIM virus inoculation when compared with control
animals treated with PBS (Fig. 4). Viral replication was also
significantly inhibited 4 d after viral inoculation in mice given
BABIM beginning either 2 or 48 h after rotaviral administra-
tion (Fig. 4).
The effect ofBABIM on animal to animal transmission of
rotavirus was also examined. For this purpose, each of five
litters (8-12 animals per litter) of 5-7-d-old suckling mice were
divided into equal thirds. One third of each litter was orally
inoculated with 100 MID100 of EDIM virus only. One third
was given 10 !l of Ca, Mg PBS orally every day at 9 and 11
a.m. and 1, 3, and 5 p.m., and one third was given 10 ,l of
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Figure 4. Effects of repeated BABIM administration on the replica-
tion of rotavirus in suckling mice. 10 gAl ofBABIM (10 Ag/ml) or Ca,
Mg PBS were administered to suckling mice at 9 and 11 a.m. and at
1, 3, and 5 p.m. beginning either 0.5, 2, 24, or 48 h after EDIM virus
inoculation. Each pair of bars represents the mean rotaviral antigen
level (±SEM) in intestinal homogenates obtained from BABIM
treated mice at 2 (first bar) or 4 (second bar) d after EDIM virus in-
oculation. Data are expressed as a percentage of the mean rotaviral
antigen level in PBS treated control animals. The number inside
each bar represents the number of animals tested. XX, animals in
this group had not received BABIM at 2 d postviral inoculation. *,











Figure 5. Effects of BABIM administration on rotaviral transmission
in suckling mice. Each of five litters of suckling mice were divided
into equal thirds. One third of each litter was given EDIM virus
only. One third of each litter was administered 10 Ml ofBABIM (10
mg/ml) daily at 9 and 11 a.m. and at 1, 3, and 5 p.m. The remaining
third of each litter served as controls and were inoculated with Ca,
Mg PBS at the same times. Each bar represents the mean rotaviral
level (±SEM) in intestinal homogenates obtained from BABIM-
treated mice. Data are expressed as a percentage of the mean rota-
viral antigen level in PBS treated control animals. *, significantly dif-
ferent (P < 0.05) from controls by Wilcoxon Rank Sum Test. #, sig-
nificantly different (0.05 < P < 0.1) from controls by Wilcoxon
Rank Sum Test.
rotaviral inoculation, intestinal tracts were collected and the
quantity of rotaviral antigen was determined by enzyme im-
munoassay. As expected, the virus-inoculated animals trans-
mitted virus to the uninoculated groups; however, 3 d after
viral inoculation mice given BABIM had significantly lower
levels of viral antigen than did control mice as determined by
the Wilcoxon Rank Sum Test (Fig. 5). 2 d later, the BABIM
treated mice still had lower levels of rotaviral antigen than did
the PBS-treated controls; however, the difference at day 5 did
not reach statistical significance.
We also used radiolabeled BABIM to investigate the phar-
macokinetics of the drug in the murine model. After intragas-
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Figure 6. Distribution of 3H in tissues and body fluids after intragas-
tric administration of 106 counts of [3H]BABIM.
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detected in all tissues and body fluids examined (Fig. 6). High
levels of label were initially present in the stomach; however,
comparable levels were not found at any other point in the
gastrointestinal tract or in the intestinal washings. Instead, the
quantity of label in the stomach declined as the label began to
appear in high concentration in plasma and urine.
Discussion
Our studies indicate that a number of protease inhibitors sup-
pressed rotaviral replication in vitro and also restricted rota-
viral replication in vivo when administered simultaneously
with virus. In addition, BABIM inhibited viral replication if
administered in multiple doses after rotaviral infection and
also limited the transmission of infection in a heavily contami-
nated environment. Repeated administration ofBABIM at the
levels used in the present studies caused an alteration in con-
sistency of the colonic contents of the suckling mice; the rota-
viral disease status thus could not be accurately assessed. The
change of fecal consistency may reflect protein maldigestion
due to inhibition of pancreatic and cellular proteases by
BABIM. Additional studies should be directed at determining
the pharmacokinetics, toxicology, and efficacy of protease in-
hibitors. Of particular importance will be the determination of
potential adverse effects of protease inhibitors on host nutri-
tion and cellular metabolism.
The mechanism by which BABIM and other protease in-
hibitors limit the in vivo and in vitro replication of rotaviruses
is most likely related to their ability to impede the proteolytic
modification of virion or cellular polypeptides that is required
for efficient cellular penetration and cell-to-cell spread
(30-32). In the case of the in vitro system used for these exper-
iments, the efficacy of the compounds for the inhibition of
rotaviral replication is probably a direct reflection of the com-
pounds' ability to inhibit exogenous trypsin. However, it is of
note that some of the compounds that displayed good levels of
in vitro inhibitory activity, such as alpha- 1 antitrypsin, soy
inhibitor and antipain had little effect on the in vivo replica-
tion of rotaviruses in experimentally infected animals. The
reason for the differences between the in vitro and in vivo
efficacy of protease inhibitors is not known with certainty but
might be related to differences in pharmacokinetics, solubility,
or cellular penetration, or to differences in the substrate speci-
ficities of the trypsin used in the in vitro experiments and the
mixture of proteolytic enzymes found in the gastrointestinal
tract. The exact mechanism ofaction ofthe protease inhibitors
as well as the nature ofthe cellular and viral proteases involved
in rotavirus replication should be the subject of additional
investigations.
Little information is currently available concerning the in
vitro or in vivo pharmacokinetics of BABIM or other diami-
dine protease inhibitors. Our preliminary studies, used a ra-
diolabeled BABIM preparation, suggested that orally adminis-
tered BABIM was rapidly absorbed from the stomach of suck-
ling mice and then excreted in the urine. Since we measured
total 3H activity rather than specific [3H]BABIM, it is possible
that we were also measuring 3H-labeled metabolic products of
BABIM in addition to the active drug. More detailed studies
on the pharmacokinetics of BABIM and related compounds
should allow for more efficient dosing regimens and formula-
tions. However, our finding of a prolonged serum half-life and
wide volume ofdistribution suggests that the administration of
these compounds might be a practical means for the preven-
tion or treatment of infections with susceptible viruses.
We found that the protease antagonists could inhibit the in
vitro generation of rotavirus plaque formation, even when the
infecting virions were preactivated by growth in trypsin (Fig.
2). This finding suggests that protease antagonists can interfere
with the cell-to-cell transmission of rotavirus infection even in
situations in which the viral surface proteins are already acti-
vated by proteolytic cleavage (26, 27). Furthermore, since the
strain of pathogenic murine rotavirus which we used for our in
vivo studies has been serially passaged by the intestinal infec-
tion of mice, it is likely that this virus was also activated by
intestinal proteases before administration to the experimental
animals. It is thus likely that, even in situations in which the
administration of BABIM does not prevent the entry of virus
into cells and the primary cycle of replication, the presence of
the drug might impede the generation of virions capable of
infecting additional cells and sustaining viral infection.
Most available chemotherapeutic agents directed at the in-
hibition of viral replication exert their activity by the inhibi-
tion of viral nucleic acid synthesis. Since there are many
shared pathways of viral and mammalian nucleotide metabo-
lism, these agents have the potential of interfering with nucleic
acid synthesis in host cells. It is thus difficult to determine with
certainty that the drugs do not have mutagenic or carcinogenic
potential, a fact which makes many of the currently available
antiviral drugs difficult to apply to the widespread treatment of
childhood viral infections. Although this mode of action can-
not be entirely ruled out for BABIM, it seems unlikely in light
of the studies of the inhibitory effect ofBABIM on the replica-
tion of respiratory syncytial virus. In this instance, it was
shown that BABIM delays viral penetration into cells by its
antiprotease action but does not interfere with viral RNA rep-
lication (30-32). Protease inhibitors such as the ones described
in this report represent a new class of viral agents that func-
tions at the level of protein interactions and would not be
expected to have such potential for long-term untoward effects
on mammalian nucleic acids. In addition, many pathogenic
viruses, including myxoviruses (38), paramyxoviruses (39),
retroviruses (40), coronaviruses (41), and poxviruses (42), re-
quire viral or host proteases for productive infection. Thus,
chemotherapeutic agents which possess protease inhibitory ac-
tivity may have a broad range of antiviral activity. The avail-
ability of antiviral agents capable of inhibiting a wide range of
pathogenic viruses without interfering with host nucleic acid
replication may represent a major advance in the prevention
and treatment of viral infections in humans and other animals.
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